Insight Molecular Diagnostics (IMDX) vs Achieve Life Sciences (QUIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Achieve Life Sciences is the larger company by market cap ($573.2 million vs $80.9 million), about 7.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMDX | QUIT |
|---|---|---|
| Share price | $1.97 | $5.56 |
| Market cap | $80.88M | $573.25M |
| 1-day change | +18.67% | -5.28% |
| YTD return | -73.73% | — |
| 1-year return | -67.38% | — |
| 5-year return | -95.91% | — |
| EPS (TTM) | $-1.27 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.05M | — |
| Revenue growth (YoY) | +115.58% | — |
| Net income (latest FY) | $-50.22M | $-54.65M |
| Gross margin | 56.67% | — |
| Operating margin | -1260.76% | — |
| Net margin | -1238.52% | — |
| 52-week high | $7.51 | $8.64 |
| 52-week low | $1.50 | $2.62 |
| Distance from 52-week high | -73.77% | -35.65% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +318.78% | +162.23% |
| Average volume | 261.88K | 1.38M |
| Shares outstanding | 41.05M | 103.10M |
| Employees | 55 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Achieve Life Sciences is about 7.1 times larger than Insight Molecular Diagnostics by market value ($573.25M vs $80.88M).
About Insight Molecular Diagnostics
IMDX stock →Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 55 employees
About Achieve Life Sciences
QUIT stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
IMDX vs QUIT FAQ
Which is bigger, Insight Molecular Diagnostics or Achieve Life Sciences?
Achieve Life Sciences (QUIT) is larger, with a market capitalization of $573.25M compared with $80.88M for Insight Molecular Diagnostics (IMDX).
Are Insight Molecular Diagnostics and Achieve Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.